Pharm-Olam International Adds Additional Offices in Latin America

Pharm-Olam International Adds Additional Offices in Latin America
HOUSTON, TEXAS June 17, 2006. Pharm-Olam International Ltd., a multi-national CRO to pharmaceutical, biotechnology, and medical device industries will expand its capabilities in Latin America by opening local offices in São Paulo, Brazil and Buenos Aires, Argentina scheduled to open in September 2006.

"From our previous experience conducting trials in these countries, we know that these areas offer great opportunities for finding treatment naïve patients, and having local offices there will improve the efficiency of Pharm-Olam's global trial logistics", said Iain Gordon, Director of Global Business Development. "Pharm-Olam has experience conducting trials throughout Latin America, where we have strong relationships with local physicians and an impressive network of sites, including some of the largest medical centers in the region."

Pharm-Olam established a local office in Mexico City in 2002, and with the additional offices in São Paulo and Buenos Aires, the company will now have a local presence in the three most populated metro areas in Latin America with an estimated combined population of over 50 million people. With some of the largest patient populations in the world, these areas offer sponsors great opportunities in patient recruitment and trial logistics.

Pharm-Olam's Latin American operations are overseen by Dr. Jorge Fiuza, who has over 15 years of clinical trial management experience in the region.

For further information about Pharm-Olam please contact Iain Gordon at igordon@pharm-olam.com.

About Pharm-Olam International
Pharm-Olam International is a multi-national contract research organization offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology and medical device industries. From pre-clinical to Phase IV, POI focuses on delivering the highest quality data, achieving targeted enrollment and meeting projected timelines.